Across TCGA pan-cancer cohorts, PSME3IP1 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated PSME3IP1 data layer compared with 24 for mass-spec protein and 8 for mass-spec protein.
The strongest signal is observed in kidney chromophobe (KICH), where higher PSME3IP1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated PSME3IP1 expression acts as an unfavorable survival marker.
KICH and UCEC are the cancer types where PSME3IP1 Mutation most reproducibly stratifies survival.